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Abstract
Background: Recent clinical studies have shown that treatment with LCZ696, a complex containing 
the angiotensin receptor blocker valsartan and neprilysin inhibitor sacubitril, improves the prognosis 
of heart failure patients with a reduced ejection fraction. This study evaluated whether LCZ696 affects 
left ventricular hypertrophy, fibrosis, and hemodynamics in isoproterenol (ISO)-treated rats compared 
with valsartan alone.
Methods: Male Wistar rats received subcutaneous saline (n = 10), subcutaneous ISO (2.4 mg/kg/day;  
n = 10), subcutaneous ISO + oral LCZ696 (60 mg/kg/day; n = 20) (ISO-LCZ), or subcutaneous  
ISO + oral valsartan (30 mg/kg/day; n = 20) (ISO-VAL) for 7 days. 
Results: LCZ696 and valsartan did not significantly reduce the increased heart weight/body weight 
ratio in rats treated with ISO. Echocardiography showed that the deceleration time shortened by ISO 
was restored by LCZ696 but not valsartan alone (p = 0.01 vs. the ISO group). Histological analysis 
showed that cardiac interstitial fibrosis increased by ISO was decreased significantly by LCZ696 but 
not valsartan alone (control: 0.10 ± 0.14%; ISO: 0.41 ± 0.32%; ISO-LCZ: 0.19 ± 0.23% [p < 0.01 
vs. the ISO group]; ISO-VAL: 0.34 ± 0.23% [p = 0.34 vs. the ISO group]). Quantitative polymerase 
chain reaction showed that mRNA expression of Tgfb1, Col1a1, Ccl2, and Anp increased by ISO was 
significantly attenuated by LCZ696 but not valsartan alone (p < 0.05 vs. the ISO group). 
Conclusions: LCZ696 improves cardiac fibrosis, but not hypertrophy, caused by continuous exposure 
to ISO in rats. (Cardiol J 2019; 26, 5: 575–583)
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Introduction
Left ventricular (LV) hypertrophy (LVH) 
is reported to be involved in heart failure with 
a preserved ejection fraction (HFpEF) [1]. HFpEF 
is associated with considerable morbidity and mor-
tality, and the risk for adverse outcomes increases 
with the severity of diastolic dysfunction [2]. 
Treatment with anti-hypertensive drugs may be 
effective to prevent HFpEF. However, randomized 
controlled trials of antihypertensive drugs, includ-
ing angiotensin-converting enzyme inhibitors and 
angiotensin receptor blockers (ARBs), have been 
generally disappointing with no convincing dem-
576 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 5
onstration of mortality or morbidity reductions 
[3–5]. Accordingly, therapies for HFpEF are of 
great clinical interest.
Inhibition of neprilysin is an attractive strategy 
to increase natriuretic peptide levels. Natriuretic 
peptides stimulate diuresis and vasodilation, im-
prove myocardial relaxation, and reduce LVH [6]. 
Recently, a first-in class dual angiotensin receptor 
and neprilysin inhibitor (ARNI), which contains 
equimolar amounts of valsartan and sacubitril, has 
been developed [7]. In the PARAMOUNT study 
(prospective comparison of ARNI with ARBs for 
management of HFpEF), LCZ696 reduced the se-
rum level of N-terminal pro-B-type natriuretic pep-
tide (NT-proBNP) more than valsartan at 12 weeks 
and was well tolerated when used for HFpEF [8]. In 
the PARADIGM-HF study (prospective comparison 
of ARNI with ACEI to determine impact on global 
mortality and morbidity in heart failure), LCZ696 
was also effective in heart failure patients with 
a reduced ejection fraction (HFrEF) [9]. However, 
the mechanism underlying the effectiveness of 
LCZ696 is poorly understood and little is known 
about its effects in HFpEF patients with LVH.
It was previously reported that continuous 
infusion of isoproterenol (ISO) induces cardiac 
hypertrophy and diastolic dysfunction in rats 
[10, 11]. The current study investigated whether 




All procedures were performed in accordance 
with the institutional guidelines for animal research 
and approved by the Animal Care and Use Com-
mittee of Okayama University (OKU-2012297).
Experimental animals and drugs
Male Wistar rats weighing 187–211 g were 
purchased from Japan SLC (Shizuoka, Japan). Rats 
were housed at an animal facility in a 12-h light-
dark cycle and were provided with standard rat 
chow and water ad libitum. LCZ696 and valsartan 
were kindly supplied by Novartis Pharma AG 
(Basel, Switzerland). LCZ696 includes molecular 
moieties of valsartan and sacubitril at a 1:1 ratio. 
L-ISO was purchased from Sigma-Aldrich (St. 
Louis, MO, USA).
Study protocol
The detailed protocol is shown in Figure 1 and 
a previous study [11]. Delivery of ISO or saline was 
performed by subcutaneously implanting an os-
motic minipump (Alzet, model 2001; 1.0 µL/h) into 
the neck under 2% isoflurane anesthesia. LCZ696 
and valsartan were dissolved in corn oil and admin-
istered by gastric gavage. Rats were divided into 
four groups and treated for 7 days: control group 
(subcutaneous HCl [pH 4] in saline, n = 10); ISO 
group (subcutaneous ISO [2.4 mg/kg/day] and oral 
corn oil, n = 10); ISO-LCZ group (subcutaneous 
ISO [2.4 mg/kg/day] and oral LCZ696 [60 mg/kg/ 
/day], n = 20); and ISO-VAL group (subcutaneous 
ISO [2.4 mg/kg/day] and oral valsartan [30 mg/ 
/kg/day], n = 20). Systolic blood pressure (SBP) 
was measured in rats using a tail cuff attached to 
a MK-2000ST Blood Pressure Monitor for Rats 
(Muromachi, Tokyo, Japan).
Hemodynamic measurements
Seven days after infusion, rats were anesthe-
tized with 2% isoflurane, and a micro-tip pressure 
transducer (Millar Instruments Inc., Houston, TX, 
USA) was inserted into the right carotid artery. The 
catheter was advanced into the LV cavity. After 
a 5 min period of stabilization, heart rate, LV sys-
tolic pressure (LVSP), LV end-diastolic pressure 
(LVEDP), and developed LV pressure (dLVP = 
= LVSP − LVEDP) were measured. For indices of 
contractility and relaxation, the maximal rates of 
increase and decrease in LVP dp/dt maximum and 
dp/dt minimum were determined. Tau was calcu-
lated according to a previous report [12].
Echocardiography
Seven days after infusion, transthoracic echo-
cardiography was performed using a 10-MHz 
phased array transducer (Aplio ver. 6.0; Toshiba, 
Tokyo, Japan) under 2% isoflurane, as described 
previously [11]. M-mode echocardiography was 
Sacrice
















Figure 1. Schematic of the treatments; ISO — subcuta-
neous isoproterenol (2.4 mg/kg/day); LCZ — LCZ2696; 
VAL — valsartan.
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performed using the parasternal short-axis view 
at the level of papillary muscles. The LV posterior 
wall thickness (PWT) and interventricular septal 
diastolic wall thickness (IVST) were measured 
during diastole (d) and systole (s), as were the LV 
internal diameter at end-diastole (LVDd) and LV 
internal diameter at end-systole (LVDs). Fractional 
shortening (FS) was then calculated according to 
the formula: FS = [(LVDd – LVDs) / LVDd] × 100. 
The apical 4-chamber view was used to assess early 
and late transmitral peak diastolic flow velocities 
(E and A waves, respectively).
Histology
The LV was fixed with 4% paraformaldehyde 
in phosphate buffered saline, embedded in paraf-
fin, and cut into 5 µm-thick sections. The sections 
were stained with Masson’s trichrome to detect 
fibrosis and examined by light microscopy. In sec-
tions stained with Masson’s trichrome, interstitial 
fibrosis was measured using computer-assisted 
image analysis, and the percentage of fibrosis was 
calculated [13, 14]. The widths of 30 individual 
cardiomyocytes were measured in each sample. 
The percentage of the fibrotic area in the LV was 
analyzed using Image J software (ver. 1.47).
Quantitative PCR
Total RNA was extracted from heart tissue 
using Trizol (Invitrogen, Carlsbad, CA, USA). 
Total RNA (2 µg) was reverse transcribed using 
ReverTra Ace (Toyobo, Osaka, Japan). cDNAs 
were diluted 5-fold before conventional reverse 
transcription-polymerase chain reaction (RT-PCR) 
amplification or 50-fold before quantitative PCR 
analysis. Real-time PCR assays were performed 
to assess gene expression of rat Tgfbeta1, Col1a1, 
Ccl2, Anp, and Gapdh using the corresponding 
primer pairs (Rn00572010_m1, Rn01523309_m, 
1 R n 0 0 6 6 4 6 3 7 _ g 1 ,  R n 0 0 5 8 0 5 5 5 _ m 1 , 
and Rn01775763_g1, respectively; Applied Bio-
systems) using the StepOnePlus Real-Time PCR 
System (Applied Biosystems). Glyceraldehyde-
3-posphate dehydrogenase (GAPDH) served as 
an internal control. The DDCt method was used 
to analyze expression level of each gene.
Measurements of NT-proBNP
Serum NT-proBNP was measured using an en-
zyme-linked immunosorbent assay (MBS704791, 
MyBioSource, San Diego, CA, USA).
Statistical analysis
Data are expressed as the mean ± standard 
deviation. For comparisons of each parameter 
among groups, statistical analysis was performed 
by analysis of variance with Bonferroni tests. 
A p-value of less than 0.05 was considered as statisti-
cally significant. Data were analyzed using SPSS 17.0 
for Windows (ver. 24; SPSS Inc., Chicago, IL, USA).
Results
Heart weights and SBP
Body weight, heart weight, and the heart-
to-body weight ratio are shown in Table 1. No 
difference was observed in body weights among 
the three groups at day 7 post-treatment with ISO, 
ISO-LCZ, and ISO-VAL. The increases in heart 
weight and heart-to-body weight ratio observed in 
the ISO group were not significantly suppressed in 
ISO-LCZ and ISO-VAL groups (p = 0.33). There 
was no difference in heart-to-body weight ratios 
between ISO-LCZ and ISO-VAL groups. Table 2 
shows the changes in SBP derived from the tail 
cuff. SBP at day 7 in ISO-LCZ and ISO-VAL groups 
was significantly suppressed compared to that in 
control and ISO groups. However, there was no 
difference in SBP at day 7 between ISO-LCZ and 
ISO-VAL groups (p = 0.11).
LV hemodynamics
Cardiac catheterization and echocardiography 
were performed at day 7 (Table 3). During cardiac 
catheterization, increases in the heart rate, LVSP, 
LVEDP, and dP/dt maximum and a decrease in 
minimum dp/dt were observed in the ISO group 
compared with the control group. LCZ696 or val-
Table 1. Effects of LCZ696 on heart weight and systolic blood pressure.
Control ISO ISO-LCZ ISO-VAL
Number of rats 10 10 20 20
Body weight [g] 242 ± 15 238 ± 8 236 ± 7 232 ± 11
Heart weight [g] 0.81 ± 0.08 1.05 ± 0.11* 0.99 ± 0.10* 0.99 ± 0.08*
Heart weight/body weight × 103 3.35 ± 0.27 4.47 ± 0.39* 4.14 ± 0.30* 4.30 ± 0.30*
*p < 0.05 vs. control. Values represent the mean ± standard deviation; ISO — isoproterenol; LCZ — LCZ696; VAL — valsartan
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sartan alone did not suppress the increased heart 
rate and LVSP. However, LCZ696 and valsartan 
alone suppressed the increases in LVEDP and dP/ 
/dt maximum significantly in ISO-LCZ and ISO-VAL 
groups compared with the control group. However, 
there were no differences in the cardiac catheteri-
zation parameters between ISO-LCZ and ISO-VAL 
groups. During echocardiography, increases in 
heart rate, IVST, and PWT and a decrease in 
the deceleration time were observed in the ISO 
group compared with the control group. LCZ696 
or valsartan alone did not suppress the IVST or 
PWT. The deceleration time shortened by ISO was 
restored by LCZ696 but not valsartan alone. There 
was significant difference in the deceleration times 
between ISO-LCZ and ISO-VAL groups (p = 0.01).
Histology
Masson’s trichrome staining revealed that 
areas of cardiac fibrosis were significantly smaller 
in ISO-LCZ group, but not in ISO-VAL group, 
compared with ISO group (area of fibrosis: control, 
0.10 ± 0.14%; ISO, 0.41 ± 0.32%; ISO-LCZ, 0.19 ± 
± 0.23%; ISO-VAL, 0.34 ± 0.23) (Fig. 2). The reduc- 
tion of cardiac fibrosis by LCZ696 was significantly 
greater than that by valsartan alone (p = 0.01).
Cardiac gene expression
Figure 3 shows mRNA expression levels in 
the heart after treatments. The gene expression 
of Tgfb1 and Clo1a1, which are involved in cardiac 
fibrosis, was significantly increased in the control 
group. LCZ696, but not valsartan, significantly 
reduced Tgfb1 and Col1a1 mRNAs (Fig. 3A, B). 
The decreases in Tgfb1 and Col1a1 expression 
in the ISO-LCZ group were significantly greater 
than those in the ISO-VAL group (p = 0.02 and 
p = 0.03, respectively). The increased expression 
of Ccl2, which is an inflammatory marker, was 
not significantly reduced by LCZ696 or valsartan 
(Fig. 3B). In addition, gene expression of Anp, which 
is a marker of a failing heart, was not decreased 
Table 3. Effects of LCZ696 on left ventricular hemodynamics and echocardiographic data.
Control (n = 10) ISO (n = 10) ISO-LCZ (n = 20) ISO-VAL (n = 20)
Cardiac catheterization
Heart rate [bpm] 408 ± 30 498 ± 36* 477 ± 54* 459 ± 30*#
LVSP [mmHg[ 101 ± 16 115 ± 10* 113 ± 9* 110 ± 14*
LVEDP [mmHg] 2.3 ± 1.3 3.5 ± 1.1* 2.5 ± 1.6 2.4 ± 1.5
dP/dtmax [mmHg/s] 8104 ± 1705 12798 ± 4227* 8450 ± 1122† 7838 ± 1246†
dP/dtmin [mmHg/s] –7107 ± 1077 –8598 ± 1837* –6941 ± 969† –6468 ± 982†
Tau [ms] 10 ± 1 10 ± 2 9 ± 2 10 ± 3
Echocardiography
LVDd [mm] 6.1 ± 0.5 6.1 ± 0.4 6.2 ± 0.4 6.1 ± 0.5
LVDs [mm] 3.5 ± 0.3 3.6 ± 0.2 3.6 ± 0.3 3.4 ± 0.3
FS [%] 44 ± 5 43 ± 7 41 ± 3 42 ± 2
IVST [mm] 1.0 ± 0.1 1.3 ± 0.1* 1.3 ± 0.1* 1.3 ± 0.1*
PWT [mm] 1.1 ± 0.1 1.4 ± 0.2* 1.4 ± 0.1* 1.3 ± 0.1*
E/A 1.5 ± 0.1 1.4 ± 0.2 1.3 ± 0.1 1.4 ± 0.2
Deceleration time [ms] 36.3 ± 4.2 34.2 ± 6.7* 38.5 ± 4.7†‡ 33.8 ± 5.5*
*p < 0.05 vs. control, †p < 0.05 vs. ISO and ‡p < 0.05 vs. ISO-VAL. Values represent the mean ± standard deviation; ISO — isoproterenol; 
LCZ — LCZ696; VAL — valsartan; LVSP — left ventricular systolic pressure; LVEDP — left ventricular end-diastolic pressure; LVDd — left ven-
tricular end-diastolic diameter; LVDs — left ventricular end-systolic diameter; FS — fractional shortening; IVST — interventricular septal thick-
ness; PWT — posterior wall thickness; E — early transmitral peak diastolic flow velocity; A — late transmitral peak diastolic flow velocity
Table 2. Change in systolic blood pressure.
Control ISO ISO-LCZ ISO-VAL
Baseline 119 ± 6 117 ± 8 120 ± 6 118 ± 5
Day 7 116 ± 3 119 ± 5 112 ± 4*† 110 ± 4*†
*p < 0.05 vs. control; †p < 0.05 vs. ISO. Values represent the mean ± standard deviation; ISO — isoproterenol; LCZ — LCZ696; VAL — valsartan
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Figure 2. Masson’s trichrome staining of hearts. Myocardial fibrosis is evident as blue staining. A. Heart sections from 
a control rat; B. Isoproterenol (ISO)-treated rat; C. ISO-treated rat administered LCZ696 (ISO-LCZ); D. ISO-treated rat 
administered valsartan (ISO-VAL). Scale bar = 100 µm. E. Bar graph shows the area of fibrosis (%). Values represent 
the mean ± standard deviation; n = 10 in control and ISO groups; n = 20 in ISO and ISO-VAL groups; *p < 0.05 vs. 
control, †p < 0.05 vs. ISO; ‡p < 0.05 vs. ISO-VAL.
by LCZ696 or valsartan (Fig. 3C). There were no 
differences in Ccl2 or Anp expression between 
ISO-LCZ and ISO-VAL groups.
Measurements of NT-proBNP
Figure 4 shows the serum NT-proBNP level 
after 7 days of treatments. The increase in the 
NT-proBNP level in the ISO group was signifi-
cantly suppressed in the ISO-LCZ group but not 
the ISO-VAL group (control, 40.1 ± 6.2 pg/mL; 
ISO, 62.4 ± 10.9 pg/mL; ISO-LCZ, 41.2 ± 9.8 pg/ 
/mL, p = 0.04 vs. ISO; ISO-VAL, 54.2 ± 9.5 pg/mL; 
p = 0.48 vs. ISO).
Discussion
In this study, it was found that short term 
treatment with LCZ696 significantly prevented 
LV fibrosis, but not LVH, caused by continuous 
infusion of ISO compared with valsartan alone. 
Additionally, significantly greater reductions in 
Tgfb1 and Col1a1 mRNA expression were induced 
by LCZ696 than valsartan alone. Echocardiography 
showed that LCZ696 significantly improved the 
decreased deceleration time, a parameter of LV 
diastolic functions, compared with valsartan alone. 
These results suggest more favorable effects of 
LCZ696 on LV fibrosis and hemodynamics in ISO-
-treated rats compared with valsartan alone.
von Lueder et al. [15] reported that LCZ696 
reduces cardiac remodeling and dysfunction after 
myocardial infarction by reducing cardiac fibrosis 
and hypertrophy in rats. Suematsu et al. [16] re-
ported that LCZ696 improves HFrEF in mice with 
streptozotocin-induced diabetes. These studies 
used a model of HFrEF, which differs from the cur-
rent study involving evaluation of a model without 
a reduced ejection fraction. As a model without 
a reduced ejection fraction, other studies evaluated 
LVH in rats with spontaneous hypertension, which 
was suppressed by valsartan [17, 18]. A model of 
chronic beta-adrenergic stimulation in rats has 
also been reported. ISO treatment for 2 weeks 
induced LVH and fibrosis that were prevented by 
an angiotensin II type I receptor blocker such as 
losartan and valsartan [19, 20]. However, a hemo-
dynamic study was not performed in these models 
of LVH. According to available research, this is the 
first animal study performed to investigate the 
hemodynamic effect of LCZ696 on LV functions 
in the rat hypertrophied heart with a preserved 
ejection fraction. Improvement in cardiac fibrosis 
by LCZ696 was consistently observed in this study 
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Figure 3. Cardiac gene expression in hearts. Total RNA was extracted from cardiac tissues and analyzed for mRNA 
expression of Tgfb1 (A), Col1a1 (B), Ccl2 (C), and Anp (D) by real-time RT-PCR analysis. ISO — isoproterenol-treated 
rats; ISO-LCZ — ISO-treated rats administered LCZ696; ISO-VAL — ISO-treated rats administered valsartan. Values 
represent the mean ± standard deviation; n = 10 in control and ISO groups; n = 20 in ISO and ISO-VAL groups; 
*p < 0.05 vs. control, †p < 0.05 vs. ISO; ‡p < 0.05 vs. ISO-VAL.
to the results obtained using rats with spontane-
ous hypertension [17], the current study did not 
reveal a protective effect on LVH by LCZ696 or 
valsartan alone. An explanation is the difference 
in mechanisms of cardiac hypertrophy and fibrosis 
induction between ISO-treated rats and spontane-
ously hypertensive rats. ISO directly affects cardiac 
hypertrophy and fibrosis in addition to elevated 
SBP. Another possibility is that the duration of 
administration in the present study was relatively 
short compared with that in previous studies. 
Therefore, a lower dose of ISO and long-term 
treatment may address these issues.
In this study, 60 mg/kg LCZ and 30 mg/kg val-
sartan was selected because several experimental 
studies using rat models employed these doses of 
valsartan and LCZ696 [16, 17, 21, 22]. The previous 
studies showed greater decreases in SBP induced 
by LCZ696 than that by valsartan alone. In contrast, 
the present study showed that SBP at day 7 did not 
statistically differ between the two groups. This 
finding suggests that a greater suppression of LV 
fibrosis by LCZ696 compared with that by valsartan 
alone is independent of blood pressure. To confirm 
this effect independently of blood pressure, future 
experiments should employ other models such 
as spontaneous hypertension rats in which blood 
pressure is matched between LCZ696 and valsartan 
groups by adjusting their doses.
There are several potential mechanisms un-
derlying the protective effect of LCZ696 in prevent-
ing ISO-induced cardiac fibrosis. In experimental 
HFrEF in streptozotocin-induced diabetic mice, 
the mRNA level of transforming growth factor beta 
(TGF-b) in the LV was reported to be suppressed 
in LCZ696 group compared with that of control 
and valsartan groups [16]. These results were in 
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significantly limited the increase in TFG-b upon 
ISO treatment. One mechanism underlying the 
suppression of TGF-a caused by specific inhibition 
of neprilysin may be the involvement of natriu-
retic peptides. First, the inhibition of neprilysin by 
sacubitril prevents breakdown of endogenous natriu-
retic peptides, which inhibits cardiac fibrosis [6]. 
Second, it has been reported that circulating an-
giotensin II levels increase after treatment with 
LCZ696 in Wistar Kyoto rats [23]. After blockade 
of angiotensin type I receptor, stimulation of 
angiotensin type II receptor via circulating angio-
tensin II would reduce cardiac fibrosis. Thus, the 
combination of angiotensin type I receptor and 
neprilysin inhibitors may augment their favorable 
effects through the angiotensin type II pathway. 
Finally, another mechanism may involve brady-
kinin. Bradykinin, which is a substrate of nepri-
lysin, has been reported to suppress myocardial 
fibrosis [24], and its effect may be enhanced by 
angiotensin receptor-blocking therapy [25]. It is 
therefore possible that neprilysin inhibitor treat-
ment contributes to cardioprotection by inhibiting 
bradykinin metabolism. Seki et al. [26] reported 
that inhibition of neprilysin with LCZ696 does not 
appear to have an additional benefit over valsar-
tan alone for the endothelial functions of arteries 
in spontaneously hypertensive rats. Their study 
suggests that vasoactive peptides, such as C-type 
natriuretic peptide, bradykinin, and substance P, 
which can accumulate because of neprilysin inhibi-
tion, may not play a crucial role in the improvement 
of endothelial functions. The difference in target 
organs between their study and this one may have 
contributed to the favorable effects of LCZ696 
compared with valsartan alone in the present 
study. Seki et al. [26] focused on endothelial func-
tions, whereas here the study focused on cardiac 
tissue including cardiomyocytes and fibroblasts. 
Another explanation is the difference in animal 
model. This rat model was simulated with ISO, 
and the elevation of blood pressure was less than 
that in a spontaneously hypertensive rat. Further 
basic and clinical studies are warranted to clarify 
the underlying mechanism of these differences.
In the current study, LCZ696 significantly im-
proved cardiac hemodynamics derived from cathe-
terization in the ISO group. LVEDP in ISO-LCZ and 
ISO-VAL groups did not increase compared with 
the control group without a significant change in 
SBP. Notably, the echocardiographic findings sug-
gested a significantly greater improvement in the 
deceleration time, a parameter of LV diastolic func-
tions, by LCZ696 compared with valsartan alone. 
It was previously reported that cardiomyocyte 
stiffness, which is associated with diastolic heart 
failure, increases in ISO-induced hypertrophied 
hearts [10]. Although cardiomyocyte stiffness was 
not evaluated directly in this study, suppression of 
cardiac fibrosis may contribute to improvement of 
diastolic dysfunction in the hypertrophied heart.
The current study demonstrated that in-
creased NT-proBNP levels in ISO group were 
significantly reduced by LCZ696 but not valsartan 
alone. Because BNP is degraded by neprilysin, 
LCZ696 may affect the BNP level. NT-proBNP, 
which is cleaved from proBNP along with BNP, is 
not a substrate of neprilysin degradation. Thus, 
a change in the NT-proBNP level reflects LV wall 
stress even under the use of LCZ696. The PARA-
MOUNT study showed that LCZ696 reduced the 
NT-proBNP level more than valsartan alone at 
12 weeks of therapy in patients with HFpEF [8]. 
Considering both these findings and those of the 
current study, LCZ696 might have a favorable effect 
on the prognosis of HFpEF patients, and a further 
large scale study evaluating cardiovascular events 
is thus warranted.
Limitations of the study
There are several limitations in this study. 
First, different doses of LCZ696 and valsartan 
Figure 4. Serum N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) was measured for 7 days after 
treatments. ISO — isoproterenol-treated rats; ISO-LCZ 
— ISO-treated rats administered LCZ696; ISO-VAL — 
ISO-treated rats administered valsartan. Values repre-
sent the mean ± standard deviation; n = 10 in control 
and ISO groups; n = 20 in ISO and ISO-VAL groups; 
*p < 0.05 vs. control; †p < 0.05 vs. ISO.
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were not tested. Therefore, dose dependencies 
of LCZ696 and valsartan in the present model 
are unknown. Second, Gu et al. [7] reported that 
plasma concentration-time profiles of valsartan are 
similar between administration of a single oral dose 
of 400 mg LCZ696 and 320 mg valsartan in healthy 
human participants. 60 mg/kg LCZ696 and 30 mg/ 
/kg valsartan was chosen, which are similar to 
those in previous studies of valsartan and LCZ696 
in rat models [16, 17, 21, 22], because pharmaco-
dynamic data for LCZ696 could not be found in 
the ISO-treated rat model. Therefore, it cannot be 
denied that the pharmacodynamics of these drugs 
may have influencedthe present results. Third, 
the duration of LCZ696 or valsartan treatments 
in the ISO-treated model was short. Long-term 
treatment may facilitate understanding the effect 
of LCZ696 on LVH, fibrosis, and hemodynamics in 
ISO-treated rats.
Conclusions
LCZ696 improved LV fibrosis caused by con-
tinuous exposure to ISO in this population of rats. 
The results suggest the possibility of using LCZ696 
to therapeutically target LVH and diastolic LV 
dysfunction.
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